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Abstract: TMEM16A is a Ca2+ activated Cl− channel with important functions in airways, intestine,
and other epithelial organs. Activation of TMEM16A is proposed as a therapy in cystic fibrosis (CF)
to reinstall airway Cl− secretion and to enhance airway surface liquid (ASL). This CFTR-agnostic
approach is thought to improve mucociliary clearance and lung function in CF. This could indeed
improve ASL, however, mucus release and airway contraction may also be induced by activators of
TMEM16A, particularly in inflamed airways of patients with asthma, COPD, or CF. Currently, both
activators and inhibitors of TMEM16A are developed and examined in different types of tissues. Here
we compare activation and inhibition of endogenous and overexpressed TMEM16A and analyze
potential off-target effects. The three well-known blockers benzbromarone, niclosamide, and Ani9
inhibited both TMEM16A and ATP-induced Ca2+ increase by variable degrees, depending on the cell
type. Niclosamide, while blocking Ca2+ activated TMEM16A, also induced a subtle but significant
Ca2+ store release and inhibited store-operated Ca2+ influx. Niclosamide, benzbromarone and
Ani9 also affected TMEM16F whole cell currents, indicating limited specificity for these inhibitors.
The compounds Eact, cinnamaldehyde, and melittin, as well as the phosphatidylinositol diC8-PIP2 are
the reported activators of TMEM16A. However, the compounds were unable to activate endogenous
TMEM16A in HT29 colonic epithelial cells. In contrast, TMEM16A overexpressed in HEK293 cells was
potently stimulated by these activators. We speculate that overexpressed TMEM16A might have a
better accessibility to intracellular Ca2+, which causes spontaneous activity even at basal intracellular
Ca2+ concentrations. Small molecules may therefore potentiate pre-stimulated TMEM16A currents,
but may otherwise fail to activate silent endogenous TMEM16A.
Keywords: TMEM16A; TMEM16F; benzbromarone; niclosamide; Ani9; TMEM16A potentiators; Eact;
PIP2
1. Introduction
The Ca2+-activated Cl− channel (CaCC) TMEM16A is expressed in epithelial and non-epithelial
cells where it contributes to a broad range of cellular functions [1]. TMEM16A produces fast gating
single channel currents of very small amplitude. TMEM16A whole cell currents are voltage dependent,
slowly activating, and outwardly rectifying. The channel conducts anions according to the Eisenman
type I selectivity sequence. In airways TMEM16A is sparsely expressed in surface epithelial cells with
somewhat larger expression in submucosal serous and mucous producing goblet cells (summarized
in [2]). TMEM16A is also expressed in airway smooth muscle (ASM) [3–6]. In both asthma and cystic
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fibrosis (CF), and upon exposure of airway epithelial cells to bacterial components, TMEM16A is
strongly upregulated, particularly in cells of submucosal glands [7–9]. In CF, impaired function of
the cystic fibrosis transmembrane conductance regulator (CFTR) leads to a defect in epithelial Cl−
secretion, causing reduced airway surface liquid (ASL) with the consequence of a dehydrated sticky
mucus and possibly low ASL pH (discussed in [2]. Pharmacological activation of TMEM16A is thought
to compensate for the absent CFTR-dependent Cl− secretion in CF, and therefore may represent a CFTR
mutation-agnostic therapy [10]. Other studies found a role of TMEM16A for ASM contraction [6,9,11].
Such a role of TMEM16A is particularly evident under inflammatory conditions like asthma, when
TMEM16A is strongly upregulated in the ASM. Because asthma appears to be a common problem
also in patients with CF [12], therapeutic activation of TMEM16A could trigger bronchoconstriction in
CF patients. Activation of TMEM16A could also trigger mucus release and enhance airway mucus
plugging [3,5,13,14].
In order to elucidate the contribution of TMEM16A to different airway functions and to define
their role in other tissues, pharmacological compounds, i.e., small molecule inhibitors and activators
of TMEM16A are frequently used. A relatively large number of small molecules have been found to
inhibit TMEM16A. These molecules are surprisingly diverse in structure and do not specifically inhibit
only TMEM16A [2]. Similarly, quite different molecules were reported to activate TMEM16A [2], with
controversial reports on their efficacy and mechanism of action. Some molecules, such as the putative
TMEM16A-activator Eact, were suspected to increase intracellular Ca2+ rather than directly activating
TMEM16A [15,16].
A recent report describes the effects of the novel TMEM16A potentiator ETX001 on fluid secretion
in cultured airway epithelia cells, and on the mucociliary clearance in sheep trachea [17]. Currently it
remains obscure how ETX001 potentiates TMEM16A activity. It will be interesting to learn more about the
mechanism of action for ETX001, and to learn whether the compound shares some functional properties
with other molecules, such as the TMEM16A-regulator phosphatidylinositol 4,5-bisphosphate (PIP2) [18,19].
Distinct binding sites for Ca2+ and PIP2 have been identified, with Ca2+ binding to transmembrane
domains 6–8 leading to opening of the channel and PIP2 binding to domains 3–5 stabilizing the channel in
the open configuration [19]. These results provide an insight into the process of Ca2+ desensitization, i.e.,
inactivation (run down) of the channel and give hints as to further developments of activators/potentiators
of TMEM16A. Along this line, our own previous results described the activation and potentiation,
respectively, of TMEM16A by the inositolphosphate INO-4995 [20].
The purpose of the present study was to compare effects of activators and inhibitors of TMEM16A
on endogenous human (h)TMEM16A and hTMEM16A overexpressed in HEK293 cells. The study
was triggered by our earlier findings showing a strong activation of overexpressed TMEM16A by
the inositolphosphate INO-4995, but a more indirect effect of INO-4995 on endogenous TMEM16A
expressed in colonic and airway epithelial cells [20]. Moreover, a basal activity at resting Ca2+
concentrations was found for overexpressed but not for endogenous TMEM16A [21]. In other studies,
TMEM16A was found to control the magnitude of local, i.e., submembranous Ca2+ signals by interacting
with the IP3 receptor [22,23]. Thus, TMEM16A modulates its own local environment in a way so that
it is activated through locally concentrated Ca2+ release [24]. In many previous studies as well as
ongoing work, inhibitors and activators of TMEM16A are used, although they may also affect other
TMEM16 paralogs or may exert additional effects on Ca2+ regulating proteins [16,25]. Here we confirm
the role of TMEM16A for intracellular Ca2+ signaling and show for a number of compounds that they
also affect TMEM16F, a paralog of TMEM16A.
2. Results
2.1. Ca2+-Dependent Cl− Transport in Colonic Epithelial Cells is not Activated by Eact
Using different mouse knockout models, we previously demonstrated that Ca2+ dependent Cl−
secretion in mouse intestine requires TMEM16A, but not TMEM16F [26]. TMEM16A is a bona fide Ca2+
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activated Cl− channel, while TMEM16F is a Ca2+ activated phospholipid scramblase that also conducts
ions [1,27–29]. Here we examined HT29 colonic epithelial cells stably expressing yellow fluorescent
protein (kindly provided by Prof. Dr. Luis Galietta, Telethon Institute of Genetics and Medicine,
Pozzuoli, Italy). We found that in HT29 cells, Cl− secretion by ATP is entirely due to the activation
of TMEM16A. It is independent of TMEM16F, as shown by siRNA-knockdown and measurement of
I- - induced YFP-quenching (Figure 1A–C). HT29 cells demonstrate strong expression of TMEM16A,
which can be well downregulated by siRNA (Figure 1D). Also CFTR is well expressed in HT29 cells,
but cAMP (I/F)-activated YFP quenching was slow and the activated whole cells currents were small
(Figure 1E–H). The compounds Eact [15] and GSK1016790, both activators of Ca2+ permeable TRPV
channels, did not activate TMEM16A in YFP-quenching experiments with HT29 cells, although TRPV4
was found to be well expressed in these cells (Figure 2A–C). Similarly, Eact or GSK1016790 did not
increase whole cell currents in patch clamp experiments (Figure 2D,E). This may correspond to the
results of a previous report, demonstrating Eact as an activator of Ca2+ permeable TRPV4 channels,
rather than a direct activator of TMEM16A [16]. Although TRPV4 is expressed in HT29 cells, the rise in
intracellular Ca2+ induced by Eact was insignificant, particularly when compared with the effect of
ATP on intracellular Ca2+ ([Ca2+]i) (Figure 2H,I). To further validate the role of TRPV4/Eact for Ca2+
signaling, we also analyzed expression of TRPV4 and the increase in intracellular Ca2+ by Eact in CFBE
airway epithelial cells and HEK293 cells (Figure 2F,G). In these two cell lines, Eact only marginally
increased intracellular Ca2+, although TRPV4 was found to be well expressed (Figure 2F,G,I,J).
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Figure 1. Endogenous Ca2+-dependent TMEM16A and cAMP-activated CFTR Cl− transport in
HT29 colonic epithelial cells. (A,B) YFP fluorescence quenching by iodide is enhanced by ATP in a
concentration-dependent manner (n = 5 for all). siRNA knockdown of TMEM16A but not TMEM16F
inhibits quenching.
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(C) Semiquantitative RT-PCR indicates knockdown of TMEM16A (T16A; 92%, n = 3) and TMEM16F
(T16F; 93%, n = 3). (D,E) Western blotting indicating pronounced expression of endogenous TMEM16A
and CFTR in HT29 cells. siRNA knocked down expression of TMEM16A. (F–H) Activation of chloride
conductance by IBMX and forskolin (I/F; 100 µM/2 µM) was not detected in iodide quenching (n = 5),
but was significant in whole cell patch clamp recordings (overlay currents and I/V curves; n = 5). Mean
± SEM. * significant activation (p < 0.05; paired t-test). # significant inhibition (p < 0.05; ANOVA).
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Figure 2. Eact does not activate endogenous Ca2+-dependent Cl− secretion, and has little effect on
[Ca2+]i. (A,B) No activation of iodide qu ching by Eact or GSK1016790 ( = 5 for both). (C) RT-PCR
indic ting the expression f TRPV4 in HT29 cells. (D,E) No activation of whole cell currents in HT29
cells by Eact or GSK1016790 (10 µM; = 5 for both). (F,G) RT-PCR of TRPV4 expressed in CFBE (F)
and HEK293 (G) cells. (H) ATP (100 µM) induced [Ca2+]i rise is inhibited by knockdown of TM M16A
but ot by Ani9 (10 µM; n = 37–105). (I,J) Minor increase in [Ca2+]i by Eact i HT29, CFBE, or HEK293
cells (n = 31–111). Mean ± SEM. # significant inhibition (p < 0.05; unpaired t-test).
2.2. Effects of Inhibitors of TMEM16A on Whole Cell Currents and Intracellular Ca2+
In previous and the present study, inhibitors of TMEM16A attenuated receptor-mediated Ca2+
increase, supp rting the role of TMEM16A Cl− currents for Ca2+ store releas (Figure 3A). On the
other hand, hysical interaction of TMEM16A with IP3-receptors was shown to augm nt local
submembraneous Ca2+ increase [23,24]. This is also shown in the present study by siRNA-knockdown
of TMEM16A: ATP-induced [Ca2+]i increase was attenuated after siRNA knockdown of TMEM16A.
Notably, after knockdown of TMEM16A, niclosamide had no further inhibitory effect on ATP-induced
Ca2+-increase (Figure 4C). In contrast, inhibition of TMEM16A by the TMM16A-blocker Ani9 [30]
did not attenuate Ca2+ signals, while it potently inhibited TMEM16A currents (Figure 3A,E,F). This
suggests that tethering of IP3-receptors, but not TMEM16A currents, are relevant for modulation of
intracellular Ca2+ levels. Many TMEM16A-inhibitors such as CaCCinhAO1, niflumic acid, niclosamide,
and benzbromarone inhibited ATP-induced Ca2+ increase in the present and in previous studies
(Figure 3A) [23,25]. Inhibition of intracellular Ca2+ signaling cold either mean that the inhibitors exert
Int. J. Mol. Sci. 2020, 21, 2557 5 of 17
this effect through inhibition of TMEM16A, or they block Ca2+ regulating proteins independent of
TMEM16A. Although Ani9 did not affect [Ca2+]i in HT29 cells it showed some inhibition on intracellular
Ca2+ in other cell types such as Cal33 and M1 mouse cells (Figure 3A). Depending on the expression
of various Ca2+ regulating proteins in the different cell lines, side effects caused by non-specificity
of small molecules might be variable in the different cell types. Both BBR and Ani9 potently
inhibited TMEM16A activated in YFP-quenching and patch clamp experiments (Figure 3B,C,E,V).
BBR also inhibited TMEM16F currents in HEK293 cells, while Ani9 changed the time dependence
and inward currents of TMEM16F (Figure 3D,G). Thus, Ani9 appears to be more specific than other
TMEM16A-inhibitors, but still affects ion currents and possibly gating properties of TMEM16F and
maybe other TMEM16 paralogs.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 18 
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Figure 3. Effect of inhibitors on Ca2+-activated Cl− transport and ATP-induced rise in [Ca2+]i.
(A) Increase in intracellular Ca2+ by stimulation of HT29 cells with ATP (100 µM). In contrast to
benzbromarone and niclosamide, Ani9 did not attenuate the effect of ATP on [Ca2+]i (n = 7–23).
In Call33 head a d neck ancer c lls an M1 mouse collecting duct cells Ani9 (10 µM) inhibited
ATP-induced Ca2+ i crease (n = 134–162) signifi antly. (B) Inhibition of ATP (5 µM) activated
YFP-quen hing in HT29 c lls by BBR (10 µM). (C) Inhibitio of ionomycin (Iono, 1 µM) activated whole
cell currents by BBR in HEK293 cells overexpressing TMEM16A (original recording and I/V curves)
(n = 5–6). (D) Inhibition of ionomycin (Iono; 1 µM) activated whole cell currents by BBR in HEK293
cells overexpressing TMEM16F (n = 6, original recording and I/V curves). (E) Inhibition of ATP (5 µM)
induced YFP-quenching in HT29 cells by Ani9. (F,G) Inhibition of ionomycin (Iono; 1 µM) activated
TMEM16A currents by Ani9 (10 µM), and change in time-dependent activation of TMEM16F currents
(n = 5–8). * significant inhibition (p < 0.05; paired t-test). # significant inhibition (p < 0.05; unpaired
t-test).
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overexpressed channels for intracellular Ca2+. This is supported by the basal activity of overexpressed 
Figure 4. Niclosamide inhibits TMEM16A currents activated by intracellular Ca2+. (A) TMEM16A
overexpressed in HEK293 cells was activated by 1 µM Ca2+ in the patch pipette filling solution. Acute
application of niclosamide (Niclo; 5 µM) significantly inhibited Ca2+-activated TMEM16A whole cell
currents (n = 7). (B) 15 min preincubation with Niclo inhibited TMEM16A more potently (n = 9–10).
(C) Increase in intracellular Ca2+ with ATP (100 µM) in HT29 cells. Niclosamide (5 µM) induces a
slight and transient increase in [Ca2+]i and inhibits ATP-induced rise in [Ca2+]i. siRNA knockdown
of TMEM16A inhibits increase in [Ca2+]i by ATP. Niclosamide shows no additional effects on [Ca2+]i
(n = 60–193). (D) ER Ca2+ store release and Ca2+ influx (SOCE) induced by CPA and niclosamide
(n = 40–50). (E,F) Effects of CPA and niclosamide on Ca2+ store release and SOCE under various
conditions (n = 40–213) * significant inhibition (p < 0.05; paired t-test). # significant inhibition (p < 0.05;
unpaired t-test).
Niclosamide was reported as potent inhibitor of TMEM16A that also inhibits TMEM16F [9,25].
Because niclosamide inhibits ATP-induced rise in [Ca2+]i [25], we examined if the compound truly
blocks TMEM16A channels directly an not or not only indirectly by affecting intracellular Ca2+
levels. To that end TMEM16A was activated by 1 µM Ca2+ in the patch pipett filling solution, to
maintain a stably nhanced intracellular Ca2+ concentration. Under these conditions niclosami e
either applied acutely or after preincubation clearly inhibited TMEM16A currents (Figu 4A,B).
Inhibition of TMEM16A was more pronounc d after short preincubation of th drug, suggesting that
the rather lipophilic drug may ac umulate in the plasma membrane which could affect TMEM16A-lipid
interaction (Figure 4A,B). Inhibition of ATP-induced [Ca2+]i increase by niclosamide was absent after
siRNA-knockout of TM M16A (Figure 4C). The SERCA-pum inhibitor cyclopiazonic acid (CPA) and,
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to a much lesser degree, niclosamide-induced ER Ca2+ store release (Figure 3D). Store operated Ca2+
entry (SOCE) after re-adding extracellular Ca2+ was not observed after niclosamide. The data suggest
that niclosamide lowers Ca2+ store content and attenuates SOCE (Figure 3D,E). Thus, niclosamide
does not only block TMEM16A and TMEM16F, but also inhibits the SERCA pump and Ca2+ influx
channels. Many lipophilic small molecules and natural compounds are known to have these side
effects. It remains currently unclear whether this is caused by a direct inhibition of Ca2+-transporting
proteins or by a more non-specific membrane lipid interaction. These additional effects of niclosamide
may contribute to the large number of its beneficial effects currently evaluated [31].
2.3. Activators of TMEM16A Act Differently on Endogenous and Overexpressed TMEM16A
Endogenous TMEM16A expressed in HEK293 cells is not activated by Eact (Figure 1). As outlined
above, no immediate activation of endogenous TMEM16A was observed for INO-4995, while
overexpressed TMEM16A was potently activated by INO-4995 [20]. Interestingly, we found a
similar result for Eact, as it potently activated both TMEM16A and TMEM16F overexpressed in
HEK293 cells (Figure 5A,B). Alerted by these results, we examined three diverse putative activators of
TMEM16A, melittin [21], cinnamaldehyde [32], and diC8-PIP2 [19,33] (Table 1). All three compounds
activated overexpressed TMEM16A (Figure 5D,F,H), but had little effect on endogenous TMEM16A
(Figure 5C,E,G). In all patch clamp experiments pipette Ca2+ was clamped to 0.1 µM. The ability of
different drugs to activate overexpressed TMEM16A may be due to a higher sensitivity of overexpressed
channels for intracellular Ca2+. This is supported by the basal activity of overexpressed TMEM16A
at a resting [Ca2+]i of 100 nM [21]. Overexpressed TMEM16A was also spontaneously active in
YFP-quenching experiments. In contrast, currents were completely absent when [Ca2+]i was clamped
to zero [21].
Table 1. Effects of potential activators/potentiators of TMEM16A in HT29 cells (endogenous TMEM16A)
and HEK293 cells (overexpressed TMEM16A).
Compound Endogenous Expressed
Activation Potentiation Activation Potentiation
Eact No (50 µM; n = 5) No (50 µM; n = 5) Yes (10 µM; n = 5) Yes (10 µM; n = 5)
GSK1016790A No (50 µM; n = 5) No (50 µM; n = 5)
Melittin Yes (2 µM; n = 5) Yes (2 µM; n = 5) Yes (0.5 µM; n = 5) Yes (0.5 µM; n = 5)
Cinnamaldehyde No (1 µM; n = 5) No (1 µM; n = 5) Yes (1 µM; n = 5) Yes (0.5 µM; n = 5)
diC8-PIP2-PL No (50 µM; n = 5) No (50 µM; n = 5) Yes (50 µM; n = 5) Yes (50 µM; n = 5)
CLCA1 No Yes
It has been reported that TMEM16A requires PIP2 to be opened by [Ca2+]i, and that PIP2
stabilizes the open conformation under high [Ca2+]i [19]. We observed that endogenous TMEM16A
currents activated by ionomycin were somewhat larger and more linear in the presence of diC8-PIP2
(Figure 6A,B). This may suggest that in the presence of PIP2, Ca2+ binding is facilitated. However,
diC8-PIP2 did not delay the rundown of endogenous TMEM16A after ionomycin-stimulation (Figure 6E).
In contrast to endogenous channels, overexpressed TMEM16A was clearly activated by diC8-PIP2 alone
(Figure 6C,D). Rundown of the channel after stimulation with ionomycin was delayed in the presence of
diC8-PIP2 (Figure 6C,D,F). Taken together, PIP2-dependent regulation is different for endogenous and
overexpressed TMEM16A [18–20,34]. In contrast to the poorly understood mechanisms of the currently
available activators of TMEM16A, such as Eact, cinnamaldehyde, ETX001, and others, the mechanism
by which the TMEM16A-activator CLCA-1 increases membrane expression of TMEM16A has been
described earlier [35]. CLCA1 is a secreted potentiator of the calcium-activated chloride channel.
Its Willebrand factor type A domain elevates TMEM16A expression and activity within minutes,
suggesting a dynamic association of TMEM16A with many partners that control its expression at
various levels [36,37]. Thus, CLCA1 appears to work by an entirely different mechanism, namely
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by stabilizing expression of TMEM16A in the plasma membrane. In contrast to small molecule
activators, which were unable to activate endogenous TMEM16A currents, exposure of the cells to a
CLCA1-enriched media strongly augmented endogenous TMEM16A currents (Figure 7A,B). Thus,
the search for activators or potentiators of TMEM16A should also consider the activatory pathway
described for CLCA1.
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Figure 5. Endogenous and overexpressed TMEM16A behave differently. (A) Activation of
overexpressed TMEM16A whole cell currents in HEK293 cells by Eact (10 µM, n = 9). (B) Activation
of TMEM16F whole cell currents in TMEM16F-overexpressing HEK293 cells by Eact (10 µM, n = 6).
(C,D) Little activation of endogenous TMEM16A currents by melittin (200 nM; n = 10) in HT29 cells,
but strong activation in HEK293 cells overexpressing TMEM16A (n = 7). (E,F) Little activation of
endogenous TMEM16A currents by cinnamaldehyde (Cinna; 1 µM; n = 9), but strong activation
of overexpressed TMEM16A (n = 5). (G,H) Little activation of endogenous TMEM16A currents by
diC8-PIP2 (50 µM; n = 6), but strong activation of overexpressed TMEM16A (n = 6). * significant
activation (p < 0.05; paired t-test). # significant activation (p < 0.05; unpaired t-test).
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and I/V curves showing effect of diC8-PIP2 (50 µM in the patch pipette filling solution) on basal and
io omycin (Iono, 0.1 µM) activate TMEM16A curre ts in HT29 cells (A,B) and HEK293 cells (C,D).
Activation of TMEM 6A by diC8-PIP2 is clearly observed in TMEM16A-overexpressing HEK293 cells
but not in HT29 cells (n = 6–7 for all). (E,F) Time cour s for Iono-activated TMEM16A currents in HT29
and HEK293 cells (n = 6–8). * significant activation (p < 0.05; paired t-test). # significant difference to
the absence of diC8-PIP2 (p < 0.05; unp ired -test).
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3. Discussion
The present study along with our previous data clearly indicate that TMEM16A is the relevant
CaCC in intestinal and airway epithelial cells (Figure 1) [26,38–40]. When analyzing TMEM16F
knockout mice, we also found no evidence for a contribution of TMEM16F to CaCC in airway or
intestinal epithelium [26] (Figure 8). We compared the effects of various drugs on endogenous
and overexpressed TMEM16A. Patch clamp experiments with a cytosolic-like buffer solution at 37
◦C [41], and YFP-quenching experiments unmasked spontaneous activity of overexpressed human
TMEM16A/F at basal (0.1 µM) intracellular Ca2+ (Figure 2) [21]. No spontaneous currents were
observed in mock transfected HEK293 cells [21], or HT29 cells. In an earlier study we analyzed potential
mechanisms for the spontaneous activity of TMEM16A, and found that activation is suppressed
by inhibition of phospholipase A2 (PLA2) [21]. Earlier results also demonstrated activation of
overexpressed TMEM16A/F by the bee toxin melittin, which stimulates PLA2, and by direct application
of lysophospholipids (LPL) [21,42]. In the present study, neither melittin nor LPL or other phospholipids
activated endogenous TMEM16A (Figure 5). In the absence of intracellular Ca2+, TMEM16A/F currents
were completely absent, indicating that binding of Ca2+ is a prerequisite for basal activity and for
the activation by different drugs [21]. We speculate that intracellular Ca2+ ions may have a better
access to overexpressed than to endogenous TMEM16A/F. Using YFP-quenching, we examined the
effects of the activators melittin (1 µM) and cinnamaldehyde (10 µM) on endogenous TMEM16A in
HT29 cells in the presence of Ca2+ increasing CPA (1 µM). However, we did not find activation of
CaCC. These results again suggest that overexpressed TMEM16A responds differently to potential
activators. Overexpressed and endogenous TMEM16A may be localized in different plasma membrane
compartments or, alternatively, accessory proteins are missing in overexpressing cells, that normally
keep the channel closed under resting [Ca2+]i.
Along this line, overexpressed TMEM16A was shown to be directly activated by the
inositolphosphate INO-4995, while INO-4995 potentiated rather than activated endogenous
TMEM16A [20,43]. Similar was observed in the present study with diC8-PIP2, which activated
TMEM16A overexpressed in HEK293 cells, but had little effects on endogenous TMEM16A in HT29 cells
(Figures 4 and 5). Our results correspond to previous publications on the regulation of TMEM16A by
PIP2: TMEM16A expressed endogenously in rat arterial smooth muscle cells was not activated but rather
inhibited by diC8-PIP2 [44], while TMEM16A overexpressed in HEK293 cells was activated [18,19].
Similar differential activation of endogenous vs. exogenous TMEM16A was observed for the
compound Eact. Eact has been reported as an activator of TMEM16A [15], but was suggested recently
to activate TMEM16A indirectly by inducing Ca2+ influx through activation of TRPV1/4 [16,45].
Currently, Eact is one of the few accessible TMEM16A activators and therefore deserved further
analysis: (i) Although TRPV4 is expressed in HT29 cells, Eact and the TRPV4-activator GSK1016790
did not activate TMEM16A. Eact caused only a very small increase in intracellular Ca2+ (Figure 1).
(ii) TMEM16A overexpressed in HEK293 cells was fully activated by Eact, while Eact-induced Ca2+
increase was only very small (Figures 1 and 5). (iii) Eact activated overexpressed TMEM16A and
TMEM16F. The present data speak in favor of Eact directly activating overexpressed TMEM16A/F at
basal [Ca2+]i. For potentiation of endogenous channels, pre-stimulation by a Ca2+-increasing agonist
may be required, which is reminiscent to the potentiator ETX001 [17]. Cinnamaldehyde also activated
overexpressed TMEM16A, with little effects on endogenous channels. The current results may be
relevant when choosing the appropriate cellular system for drug testing or high throughput screening.
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Figure 8. TMEM16F does not contribute to ion transport in mouse airways. Original Ussing chamber
recordings obtained under open circuit conditions in tracheas from TMEM16Ffl/fl (wild type) (A,C) and
TMEM16Ffl/flFoxJ1Cre (TMEM16F knockout in ciliated airway epithelial cells) (B,D) mice. Inhibition of
epithelial Na+ absorption (via ENaC) by amiloride (10 µM), activation of CFTR by IBMX and forskolin
(100 µM and 2 µM; cAMP), and activation of Ca2+-dependent Cl− secretion by luminal ATP (100 µM)
and basolateral carbachol (CCH; 100 µM) were comparable in wild type and TMEM16F-knockout
tracheas. (E) Summaries of the calculated short circuit currents. Mean ± SEM (4 tracheas for each
series).
The present study also compared inhibition of endogenous and overexpressed TMEM16A. Here
the results were more consistent, i.e., the inhibitors examined here ( enzbromarone, niclosamide,
A i9) blocked both endogenous and overexpressed channels (Figure 2). There are, however, issues
regarding the specificity of these inhi itors. We reported earlier that niclosamide, apart from inhibiting
TMEM16A, also inhibits TMEM16F [25]. Similar is shown in the present report for benzbromarone.
Ani9 [30] showed some effects on time-dependent activation of TMEM16F currents (Figure 2). Ani9 did
not block ATP-induced Ca2+ rise in HT29 cells, but sh wed some inhibitory effects on [Ca2+]i in Cal33
and M1 cells (Figure 2). In contrast, benzbromarone and niclosamide clearly inhibited Ca2+ increase by
stimulation with ATP (Figure 2). The data provide evidence that niclosamide lowers the Ca2+ store
content and dampens Ca2+ influx (Figure 3). Nevertheless, when intracellular Ca2+ was clamped to
1 µM, niclosamide consistently inhibite TMEM16A (Figure 3A,B). The fact that TMEM16A enhances
local Ca2+ signals by tethering the IP3 receptor complicates the analysis [22,23,26,46]. Moreover, some
TMEM16A compounds were sho n by Bill et al. to result in TMEM16A degradation, which may
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contribute to inhibition of Ca2+ signals [47]. Alternatively, it is conceivable that TMEM16A inhibitors
that modulate ATP-induced intracellular calcium, could also interfere with other TMEM16A interacting
partners to modulate channel activation and increase [Ca2+]i. Thus, Liu et al. (2020) found endophilin
A2 regulated TMEM16A by autophagy-mediated degradation [48].
This somewhat convoluted situation calls for attention when interpreting physiological effects of
inhibitors and activators of TMEM16A. In addition, voltage clamp experiments with voltage-gated
TMEM16A channels may provide different results than experiments under non-voltage clamped
conditions (YFP quenching). It is therefore indispensable to confirm results with novel small molecules
by using knockdown technologies in vitro and TMEM16A-knockout animals [5,25,49]. The diversity
of molecules that have been reported to inhibit or activate TMEM16A raises questions as to their
specificity. As hypothesized earlier, interference of these molecules with plasma membrane lipids may
be part of the mechanism of action. The present data as well as recent reports on the activation of
the channel by lipid peroxidation [50], PLA2 [21,42], inositolphosphates such as INO-4995 [20], PIP2,
cholesterol, and fatty acids [18,51] strongly support a regulation of TMEM16A by plasma membrane
lipids [21].
4. Material and Methods
4.1. Knockout Animals
Generation of mice with a floxed TMEM16F allele was described previously [52]. For KO of
TMEM16F in ciliated airway epithelial, TMEM16Ffl/fl mice were crossed with FoxJ1-Cre mice [53].
All animal experiments were approved by the local ethics committee of the Government of
Unterfranken/Würzburg (AZ: 55.2-2532-2-328, approved on 3 April 2017) and were conducted according
to the guidelines of the American Physiological Society and the German law for the welfare of animals.
4.2. Cell Culture
All cells were grown at 37 ◦C in a humidified atmosphere with 5% (v/v) CO2. HT29 human
colonic carcinoma epithelial cells stably overexpressing iodide-sensitive enhanced yellow fluorescent
protein (eYFP-I152L; HT29-YFP) were cultured in McCoy’s 5A medium supplemented with 10%
(v/v) fetal bovine serum (FBS) and 1 mg/mL G418 selection antibiotic (all from Capricorn Scientific,
Ebsdorfergrund, Germany). Human embryonic kidney HEK293 stably coexpressing TMEM16A
and eYFP-I152L (HEK-TMEM16A-YFP) were grown in DMEM low glucose medium supplemented
with 10% (v/v) FBS, 1% (v/v) L-glutamine 200 mM and 10 mM HEPES (all from Capricorn Scientific,
Ebsdorfergrund, Germany), in the presence of selection antibiotics puromycin 0.5µg/mL (Sigma-Aldrich
Chemie GmbH, 82024 Taufkirchen, Germany) and hygromycin B 150 µg/mL (Capricorn Scientific,
Ebsdorfergrund, Germany). Mouse collecting duct cell line (M1) was cultured in DMEM/F12 medium
supplemented with 5% (v/v) fetal bovine serum (FBS), 1% (v/v) insulin-transferrin-selenium (ITS) 100×,
and 1% (v/v) l-glutamine 200mM (all from Capricorn Scientific, Ebsdorfergrund, Germany). Squamous
cell tongue carcinoma cell line Cal-33 was cultured in DMEM low glucose medium supplemented with
10% (v/v) FBS (all from Capricorn Scientific, Ebsdorfergrund, Germany).
Construction of expression plasmids has been described previously [21]. HEK293 cells were
seeded in fibronectin- and collagen-coated 18-mm coverslips and transfected with bicistronic IRES
plasmid vectors encoding hTMEM16A, hTMEM16F, or empty pcDNA3.1 vector (mock) and CD8
for detection of transfected cells by binding of anti-CD8 labeled beads, using standard protocols for
Lipofectamine 3000. All experiments were performed 48–72 h after transfection.
Knockdown of TMEM16 proteins in HT29-YFP cells was performed through transfection by
electroporation of siTMEM16A or siTMEM16F (both from Invitrogen, Carlsbad, CA, USA), using a
neon transfection system (Invitrogen, Carlsbad, CA, USA) with a program of 3 pulses, 1650 V, 10 ms.
Alternatively, the siRNAs were transfected using standard protocols for Lipofectamine 3000 (Invitrogen,
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Carlsbad, CA, USA). Scrambled siRNA (Invitrogen, Carlsbad, CA, USA) was transfected as control.
All cells transfected with siRNA were used for experiments 72 h after transfection.
4.3. RT-PCR
For RT-PCR total RNA from cell lines was isolated using NucleoSpin RNA II columns
(Macherey-Nagel, Düren, Germany). Total RNA (1 µg/50 µL reaction) was reverse-transcribed using
random primers and M-MLV Reverse Transcriptase RNase H Minus (all from Promega, Mannheim,
Germany). Each RT-PCR reaction contained sense and antisense primers (0.5 µM) (Table 2), 0.5 µL
cDNA, and GoTaq Polymerase (all from Promega, Mannheim, Germany). After 2 min at 95 ◦C, cDNA
was amplified (25–35 cycles for target sequence and 25 cycles for the reference GAPDH) for 30 s at 95
◦C, 30 s at 56 ◦C, and 1 min at 72 ◦C. PCR products were then visualized by loading on peqGREEN-
(Peqlab, Düsseldorf, Germany) -containing agarose gels and analyzed using ImageJ.
Table 2. RT-PCR primers.
Target Primers PCR Product
TMEM16A
forward: 5’-CGACTACGTGTACATTTTCCG 445 bp
reverse: 5´-GATTCCGATGTCTTTGGCTC
TMEM16F
forward: 5´-GGAGTTTTGGAAGCGACGC 325 bp
reverse: 5´-GTATTTCTGGATTGGGTCTG
TRPV4
forward: 5´-GCCCCACATTGTCAACTACC 490 bp
reverse: 5´-CCGCAGCAGTTCATTGATGG
GAPDH
forward: 5´-GTATTGGGCGCCTGGTCAC 200 bp
reverse: 5´-CTCCTGGAAGATGGTGATGG
4.4. Western Blotting
Protein was isolated from cells using a sample buffer containing 50 mM Tris-HCl, 150 mM NaCl,
50 mM Tris, 100 mM dithiothreitol, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 1% protease
inhibitor mixture (Sigma-Aldrich, St. Louis, MO, USA). Proteins were separated by 7.5% SDS-PAGE
and transferred to a PVDF membrane (GE Healthcare, Munich, Germany). Membranes were incubated
with primary rabbit polyclonal anti-TMEM16A DOG1 antibody (#NBP1-49799, Novus Biologicals,
Centennial, CO, USA; 1:500 in 1% (w/v) NFM/TBS-T) overnight at 4 ◦C. The CFTR antibody was from
Alomone Labs (Israel). Membranes were then incubated with horseradish peroxidase (HRP)-conjugated
goat anti-rabbit secondary antibody at RT for 2 h and immunoreactive signals were visualized using
supersignal chemiluminescence substrate detection kit (Pierce Biotechnology, Rockford, IL, USA).
Actin (1:10,000) was used as a loading control.
4.5. Patch Clamping
Cells were grown on fibronectin and collagen-coated glass coverslips for patch clamp experiments.
Coverslips were mounted in a perfused bath chamber on the stage of an inverted microscope (IM35,
Zeiss, Oberkochen, Germany) and kept at 37 ◦C. Patch pipettes were filled with a cytosolic-like solution
containing in mM: KCl 30, K+-Gluconate 95, NaH2PO4 1.2, Na2HPO4 4.8, EGTA 1, Ca2+-Gluconate
0.758, MgCl2 1.03, D-Glucose 5, ATP 3, pH 7.2. The Ca2+ activity was 0.01, 0.1, or 1 µM. The bath was
perfused continuously with Ringer solution at a rate of 8 mL/min. Patch clamp experiments were
performed in the fast whole cell configuration. Patch pipettes had an input resistance of 2–4 MΩ
when filled with cytosolic-like solution. The access conductance was monitored continuously and
was 60–140 nS. Currents (voltage clamp) and voltages (current clamp) were recorded using a patch
clamp amplifier (EPC 7, List Medical Electronics, Darmstadt, Germany), the LIH1600 interface and
PULSE software (HEKA, Lambrecht, Germany) as well as Chart software (AD Instruments, Spechbach,
Germany). Data were stored continuously on a computer hard disc and analyzed using PULSE
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software. In regular intervals, membrane voltage (Vc) was clamped in steps of 20 mV from −100 to
+100 mV from a holding voltage of −100 mV. Current density was calculated by dividing whole cell
currents by cell capacitance.
4.6. Iodide-Sensitive YFP-Quenching Assay of Anion Conductance/TMEM16A Activity
Cells stably transfected with iodide-sensitive YFP were plated in transparent, 96-well plates
(Sarstedt, Nümbrecht, Germany), cultured 24–72 h to 80–90% confluence, washed with gluconate
substituted-Ringer solution (mmol/L: NaCl 100–120; Na+-gluconate 20–40; KCl 5; MgCl2 1; CaCl2
2; D-Glucose 10; HEPES 10), and incubated with or without test compounds in this solution. Total
intracellular YFP fluorescence intensity in each well was measured in a fluorescence microplate reader
(NOVOstar, BMG Labtech, Ortenberg, Germany) kept at 37 ◦C, using an excitation wavelength of
485 nm and emission detection at 520 nm. Fluorescence was read continuously during injection
of an iodide (I−)-substituted Ringer solution (mmol/L: NaCl 100–120; NaI 20–40; KCl 5; MgCl2 1;
CaCl2 2; D-Glucose 10; HEPES 10) by a syringe pump and following injections of a symmetrical
Ringer solution (in mmol/L: NaCl 100–120; Na+-Gluconate 10–20; NaI 10–20; KCl 5; MgCl2 1; CaCl2
2; D-Glucose 10; HEPES 10) carrying test compounds. Original data were collected, background
fluorescence was subtracted, and the initial rate of maximal fluorescence decay caused by I- influx/YFP
fluorescence-quenching upon acute injection (or pre-incubation) of test compounds was measured to
determine anion conductance/activity of TMEM16A.
4.7. Ca2+ Measurements
Cells were seeded on glass cover slips and loaded with 2 µM Fura-2/AM and 0.02% pluronic F-127
(Invitrogen, Darmstadt, Germany) in Ringer solution (mmol/L: NaCl 145; KH2PO4 0,4; K2HPO4 1,6;
Glucose 5; MgCl2 1; Ca2+-Gluconate 1,3) for 1 h at room temperature. Fluorescence was detected in
cells perfused with Ringer’s solution at 37 ◦C using an inverted microscope (Axiovert S100, Zeiss,
Oberkochen, Germany) and a high speed polychromator system (VisiChrome, Puchheim, Germany).
Fura-2 was excited at 340/380 nm, and emission was recorded between 470 and 550 nm using a
CoolSnap camera (CoolSnap HQ, Visitron). [Ca2+]i was calculated from the 340/380 nm fluorescence
ratio after background subtraction. The formula used to calculate intracellular calcium ([Ca2+]i) was
[Ca2+]i =Kd × (R − Rmin)/(Rmax − R) × (Sf2/Sb2), where R is the observed fluorescence ratio. The values
Rmax and Rmin (maximum and minimum ratios) and the constant Sf2/Sb2 (fluorescence of free and
Ca2+-bound Fura-2 at 380 nm) were calculated using 1 µmol/L ionomycin (Calbiochem, La Jolla, CA,
USA), 5 µmol/L nigericin (Sigma-Aldrich, St. Louis, MO, USA), 10 µmol/L monensin (Sigma-Aldrich,
St. Louis, MO, USA), and 5 mmol/L EGTA to equilibrate intracellular and extracellular Ca2+ in intact
Fura-2-loaded cells. The dissociation constant for the Fura-2•Ca2+ complex was taken as 224 nmol/L.
Control of experiment, imaging acquisition, and data analysis were done with the software package
Meta-Fluor (Universal Imaging, New York, NY, USA).
4.8. Data and Statistical Analysis
If not indicated otherwise, all chemicals were from Sigma-Aldrich. Data are shown as individual
traces or as summaries with mean values ± SEM and number of experiments or cells given in each
figure’s legend. For statistical analysis, paired or unpaired Student’s t-test was used as appropriate. A
p-value < 0.05 was accepted as statistically significant difference (indicated by # for unpaired data and
by * for paired data).
Author Contributions: R.C., I.C., R.B., K.T., and J.O. performed experiments, R.C., I.C., J.O., R.S., J.K.S. and
K.K. analyzed data and wrote the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This research was supported by UK CF Trust SRC013, DFG KU756/14-1, Mukoviszidose e.V. and
Gilead Stiftung.
Int. J. Mol. Sci. 2020, 21, 2557 15 of 17
Acknowledgments: We thank Luis Galietta (Telethon Institute of Genetics and Medicine, Pozzuoli, Italy) for
providing the HT29/YFP cell line.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Pedemonte, N.; Galietta, L.J. Structure and Function of TMEM16 Proteins (Anoctamins). Physiol. Rev. 2014,
94, 419–459. [CrossRef] [PubMed]
2. Kunzelmann, K.; Ousingsawat, J.; Cabrita, I.; Doušová, T.; Bähr, A.; Janda, M.; Schreiber, R.; Benedetto, R.
TMEM16A in Cystic Fibrosis: Activating or Inhibiting? Front. Pharmacol. 2019, 10, 3. [CrossRef] [PubMed]
3. Huang, F.; Zhang, H.; Wu, M.; Yang, H.; Kudo, M.; Peters, C.J.; Woodruff, P.G.; Solberg, O.D.; Donne, M.L.;
Huang, X.; et al. Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway
smooth muscle contraction. Proc. Natl. Acad. Sci. USA 2012, 109, 16354–16359. [CrossRef] [PubMed]
4. Gallos, G.; Remy, K.E.; Danielsson, J.; Funayama, H.; Fu, X.W.; Chang, H.Y.; Yim, P.D.; Xu, D.; Emala, C.W., Sr.
Functional Expression of the TMEM16 Family of Calcium Activated Chloride Channels in Airway Smooth
Muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 305, L625–L634. [CrossRef]
5. Benedetto, R.; Cabrita, I.; Schreiber, R.; Kunzelmann, K. TMEM16A is indispensable for basal mucus secretion
in airways and intestine. FASEB J. 2019, 33, 4502–4512. [CrossRef]
6. Zhang, C.H.; Li, Y.; Zhao, W.; Lifshitz, L.M.; Li, H.; Harfe, B.D.; Zhu, M.S.; ZhuGe, R. The transmembrane
protein 16A Ca(2+)-activated Cl− channel in airway smooth muscle contributes to airway hyperresponsiveness.
Am. J. Respir. Crit. Care Med. 2013, 187, 374–381. [CrossRef]
7. Caci, E.; Scudieri, P.; Di Carlo, E.; Morelli, P.; Bruno, S.; De, F.I.; Bragonzi, A.; Gianotti, A.; Sondo, E.;
Ferrera, L.; et al. Upregulation of TMEM16A Protein in Bronchial Epithelial Cells by Bacterial Pyocyanin.
PLoS ONE 2015, 10, e0131775. [CrossRef]
8. Zhang, Y.; Wang, X.; Wang, H.; Jiao, J.; Li, Y.; Fan, E.; Zhang, L.; Bachert, C. TMEM16A-Mediated Mucin
Secretion in IL-13-Induced Nasal Epithelial Cells From Chronic Rhinosinusitis Patients. Allergy Asthma
Immunol. Res. 2015, 7, 367–375. [CrossRef]
9. Miner, K.; Labitzke, K.; Liu, B.; Elliot, R.; Wang, P.; Henckels, K.; Gaida, K.; Elliot, R.; Chen, J.J.; Liu, L.; et al.
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists
That Fully Bronchodilate Airways. Front. Pharmacol. 2019, 10, 51. [CrossRef]
10. Fajac, I.; De Boeck, K. New horizons for cystic fibrosis treatment. Pharmacol. Ther. 2017, 170, 205–211.
[CrossRef]
11. Wang, P.; Zhao, W.; Sun, J.; Tao, T.; Chen, X.; Zheng, Y.Y.; Zhang, C.H.; Chen, Z.; Gao, Y.Q.; She, F.;
et al. Inflammatory mediators mediate airway smooth muscle contraction through a G protein-coupled
receptor-transmembrane protein 16A-voltage-dependent Ca(2+) channel axis and contribute to bronchial
hyperresponsiveness in asthma. J. Allergy Clin. Immunol. 2018, 141, 1259–1268.e1211. [CrossRef] [PubMed]
12. Kent, B.D.; Lane, S.J.; van Beek, E.J.; Dodd, J.D.; Costello, R.W.; Tiddens, H.A. Asthma and cystic fibrosis: A
tangled web. Pediatr. Pulmonol. 2014, 49, 205–213. [CrossRef] [PubMed]
13. Kang, J.W.; Lee, Y.H.; Kang, M.J.; Lee, H.J.; Oh, R.; Min, H.J.; Namkung, W.; Choi, J.Y.; Lee, S.N.; Kim, C.H.;
et al. Synergistic mucus secretion by histamine and IL-4 through TMEM16A in airway epithelium. Am. J.
Physiol. Lung Cell. Mol. Physiol. 2017. [CrossRef] [PubMed]
14. Lin, J.; Jiang, Y.; Li, L.; Liu, Y.; Tang, H.; Jiang, D. TMEM16A mediates the hypersecretion of mucus induced
by Interleukin-13. Exp. Cell Res. 2015, 334, 260–269. [CrossRef]
15. Namkung, W.; Yao, Z.; Finkbeiner, W.E.; Verkman, A.S. Small-molecule activators of TMEM16A, a
calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB
J. 2011, 25, 4048–4062. [CrossRef]
16. Genovese, M.; Borrelli, A.; Venturini, A.; Guidone, D.; Caci, E.; Viscido, G.; Gambardella, G.; di Bernardo, D.;
Scudieri, P.; Galietta, L.J.V. TRPV4 and purinergic receptor signalling pathways are separately linked in
airway epithelia to CFTR and TMEM16A chloride channels. J. Physiol. 2019. [CrossRef]
17. Danahay, H.L.; Lilley, S.; Fox, R.; Charlton, H.; Sabater, J.; Button, B.; McCarthy, C.; Collingwood, S.P.;
Gosling, M. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
Am. J. Respir. Crit. Care Med. 2020. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2557 16 of 17
18. De Jesus-Perez, J.J.; Cruz-Rangel, S.; Espino-Saldana, A.E.; Martinez-Torres, A.; Qu, Z.; Hartzell, H.C.;
Corral-Fernandez, N.E.; Perez-Cornejo, P.; Arreola, J. Phosphatidylinositol 4,5-bisphosphate, cholesterol,
and fatty acids modulate the calcium-activated chloride channel TMEM16A (ANO1). Biochim. Biophys. Acta
2017, 1863, 299–312. [CrossRef]
19. Le, S.C.; Jia, Z.; Chen, J.; Yang, H. Molecular basis of PIP2-dependent regulation of the Ca(2+)-activated
chloride channel TMEM16A. Nat. Commun. 2019, 10, 3769. [CrossRef]
20. Tian, Y.; Schreiber, R.; Wanitchakool, P.; Kongsuphol, P.; Sousa, M.; Uliyakina, I.; Palma, M.; Faria, D.;
Traynor-Kaplen, A.E.; Fragata, J.I.; et al. Control of TMEM16A by INO-4995 and other inositolphosphates.
Br. J. Pharmacol. 2013, 168, 253–265. [CrossRef]
21. Schreiber, R.; Ousingsawat, J.; Wanitchakool, P.; Sirianant, L.; Benedetto, R.; Reiss, K.; Kunzelmann, K.
Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and phospholipid scrambling by Ca2+
and plasma membrane lipid. J. Physiol. (Lond.) 2018, 596, 217–229. [CrossRef] [PubMed]
22. Jin, X.; Shah, S.; Liu, Y.; Zhang, H.; Lees, M.; Fu, Z.; Lippiat, J.D.; Beech, D.J.; Sivaprasadarao, A.; Baldwin, S.A.;
et al. Activation of the Cl− Channel ANO1 by Localized Calcium Signals in Nociceptive Sensory Neurons
Requires Coupling with the IP3 Receptor. Sci. Signal. 2013, 6, ra73. [CrossRef] [PubMed]
23. Cabrita, I.; Benedetto, R.; Fonseca, A.; Wanitchakool, P.; Sirianant, L.; Skryabin, B.V.; Schenk, L.K.;
Pavenstadt, H.; Schreiber, R.; Kunzelmann, K. Differential effects of anoctamins on intracellular calcium
signals. FASEB J. 2017, 31, 2123–2134. [CrossRef] [PubMed]
24. Jin, X.; Shah, S.; Du, X.; Zhang, H.; Gamper, N. Activation of Ca2+-activated Cl− channel ANO1 by localized
Ca2+ signals. J. Physiol. 2016, 594, 19–30. [CrossRef] [PubMed]
25. Cabrita, I.; Benedetto, R.; Schreiber, R.; Kunzelmann, K. Niclosamide repurposed for the treatment of
inflammatory airway disease. JCI insight 2019, 8, 128414. [CrossRef]
26. Schreiber, R.; Faria, D.; Skryabin, B.V.; Rock, J.R.; Kunzelmann, K. Anoctamins support calcium-dependent
chloride secretion by facilitating calcium signaling in adult mouse intestine. Pflügers Arch. 2015, 467,
1203–1213. [CrossRef]
27. Shimizu, T.; Iehara, T.; Sato, K.; Fujii, T.; Sakai, H.; Okada, Y. TMEM16F is a component of a Ca2+-activated
Cl− channel but not a volume-sensitive outwardly rectifying Cl− channel. Am. J. Physiol. Cell. Physiol. 2013,
304, C748–C759. [CrossRef]
28. Grubb, S.; Poulsen, K.A.; Juul, C.A.; Kyed, T.; Klausen, T.K.; Larsen, E.H.; Hoffmann, E.K. TMEM16F
(Anoctamin 6), an anion channel of delayed Ca2+ activation. J. Gen. Physiol. 2013, 141, 585–600. [CrossRef]
29. Ousingsawat, J.; Wanitchakool, P.; Kmit, A.; Romao, A.M.; Jantarajit, W.; Schreiber, S.; Kunzelmann, K.
Anoctamin 6 mediates effects essential for innate immunity downstream of P2 × 7-receptors in macrophages.
Nat. Commun. 2015, 6, 1–10. [CrossRef]
30. Seo, Y.; Lee, H.K.; Park, J.; Jeon, D.K.; Jo, S.; Jo, M.; Namkung, W. Ani9, A Novel Potent Small-Molecule
ANO1 Inhibitor with Negligible Effect on ANO2. PLoS ONE 2016, 11, e0155771. [CrossRef]
31. Kadri, H.; Lambourne, O.A.; Mehellou, Y. Niclosamide, a Drug with Many (Re)purposes. ChemMedChem
2018, 13, 1088–1091. [CrossRef] [PubMed]
32. Huang, Y.; Guo, S.; Ren, S.; Chen, Y.; Zhan, Y.; An, H. The Natural Compound Cinnamaldehyde is a Novel
Activator of Calcium-Activated Chloride Channel. J. Membr. Biol. 2018, in press. [CrossRef] [PubMed]
33. Arreola, J.; Hartzell, H.C. Wasted TMEM16A channels are rescued by phosphatidylinositol 4,5-bisphosphate.
Cell Calcium 2019, 84, 102103. [CrossRef] [PubMed]
34. Tembo, M.; Wozniak, K.L.; Bainbridge, R.E.; Carlson, A.E. Phosphatidylinositol 4,5-bisphosphate (PIP2) and
Ca(2+) are both required to open the Cl(−) channel TMEM16A. J. Biol. Chem. 2019. [CrossRef]
35. Sala-Rabanal, M.; Yurtsever, Z.; Nichols, C.G.; Brett, T.J. Secreted CLCA1 modulates TMEM16A to activate
Ca(2+)-dependent chloride currents in human cells. Elife 2015, 4, e05875. [CrossRef]
36. Sala-Rabanal, M.; Yurtsever, Z.; Berry, K.N.; Nichols, C.G.; Brett, T.J. Modulation of TMEM16A channel
activity by the von Willebrand factor type A (VWA) domain of the calcium-activated chloride channel
regulator 1 (CLCA1). J. Biol. Chem. 2017, 292, 9164–9174. [CrossRef]
37. Berry, K.N.; Brett, T.J. Structural and Biophysical Analysis of the CLCA1 VWA Domain Suggests Mode of
TMEM16A Engagement. Cell Rep. 2020, 30, 1141–1151.e1143. [CrossRef]
38. Ousingsawat, J.; Martins, J.R.; Schreiber, R.; Rock, J.R.; Harfe, B.D.; Kunzelmann, K. Loss of TMEM16A causes
a defect in epithelial Ca2+ dependent chloride transport. J. Biol. Chem. 2009, 284, 28698–28703. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2557 17 of 17
39. Rock, J.R.; O’Neal, W.K.; Gabriel, S.E.; Randell, S.H.; Harfe, B.D.; Boucher, R.C.; Grubb, B.R. Transmembrane
protein 16A (TMEM16A) is a Ca2+ regulated Cl−—Secretory channel in mouse airways. J. Biol. Chem. 2009,
284, 14875–14880. [CrossRef]
40. Benedetto, R.; Ousingsawat, J.; Wanitchakool, P.; Zhang, Y.; Holtzman, M.J.; Amaral, M.; Rock, J.R.;
Schreiber, R.; Kunzelmann, K. Epithelial Chloride Transport by CFTR Requires TMEM16A. Sci. Rep. 2017, 7,
12397. [CrossRef]
41. Greger, R.; Kunzelmann, K. Simultaneous recording of the cell membrane potential and properties of the cell
attached membrane of HT29 colon carcinoma and CF-PAC cells. Pflügers Arch. 1991, 419, 209–211. [CrossRef]
[PubMed]
42. Sirianant, L.; Ousingsawat, J.; Wanitchakool, P.; Schreiber, R.; Kunzelmann, K. Cellular Volume regulation by
Anoctamin 6:Ca2+, phospholipase A2,osmosensing. Pflügers Arch. 2015, 468, 335–349. [CrossRef] [PubMed]
43. Vajanaphanich, M.; Schultz, C.; Rudolf, M.T.; Wasserman, M.; Enyedi, P.; Craxton, A.; Shears, S.B.; Tsien, R.Y.;
Barrett, K.E.; Traynor-Kaplan, A.E. Long-term uncoupling of chloride secretion from intracellular calcium
levels by Ins(3,4,5,6)P4. Nature 1994, 371, 711–714. [CrossRef] [PubMed]
44. Pritchard, H.A.; Leblanc, N.; Albert, A.P.; Greenwood, I.A. Inhibitory role of phosphatidylinositol 4,5
bisphosphate on TMEM16A encoded calcium-activated chloride channels in rat pulmonary artery. Br. J
Pharmacol. 2014, 171, 4311–4321. [CrossRef]
45. Liu, S.; Feng, J.; Luo, J.; Yang, P.; Brett, T.J.; Hu, H. Eact, a small molecule activator of TMEM16A, activates
TRPV1 and elicits pain- and itch-related behaviors. Br. J. Pharmacol. 2016, 173, 1208–1218. [CrossRef]
[PubMed]
46. Kunzelmann, K.; Ousingsawat, J.; Benedetto, R.; Cabrita, I.; Schreiber, R. Contribution of Anoctamins to Cell
Survival and Cell Death. Cancers 2019, 19, 382. [CrossRef] [PubMed]
47. Bill, A.; Hall, M.L.; Borawski, J.; Hodgson, C.; Jenkins, J.; Piechon, P.; Popa, O.; Rothwell, C.; Tranter, P.;
Tria, S.; et al. Small molecule-facilitated degradation of ANO1 protein: A new targeting approach for
anticancer therapeutics. J. Biol. Chem. 2014, 289, 11029–11041. [CrossRef]
48. Liu, C.Z.; Li, F.Y.; Lv, X.F.; Ma, M.M.; Li, X.Y.; Lin, C.X.; Wang, G.L.; Guan, Y.Y. Endophilin A2 regulates
calcium-activated chloride channel activity via selective autophagy-mediated TMEM16A degradation. Acta
Pharmacol. Sin. 2020, 41, 208–217. [CrossRef]
49. Benedetto, R.; Ousingsawat, J.; Cabrita, I.; Pinto, M.; Lerias, J.; Wanitchakool, P.; Schreiber, R.; Kunzelmann, K.
Plasma membrane localized TMEM16 Proteins are Indispensable for expression of CFTR. J. Mol. Med. 2019,
97, 711–722. [CrossRef]
50. Schreiber, R.; Buchholz, B.; Kraus, A.; Schley, G.; Scholz, J.; Ousingsawat, J.; Kunzelmann, K. Lipid
peroxidation drives renal cyst growth in vitro through activation of TMEM16A. J. Am. Soc. Nephrol. 2019, 30,
228–242. [CrossRef]
51. Kunzelmann, K.; Tilmann, M.; Hansen, C.P.; Greger, R. Inhibition of epithelial chloride channels by cytosol.
Pflügers Arch. 1991, 418, 479–490. [CrossRef] [PubMed]
52. Schenk, L.K.; Ousingsawat, J.; Skryabin, B.V.; Schreiber, R.; Pavenstadt, H.; Kunzelmann, K. Regulation and
Function of TMEM16F in Renal Podocytes. Int. J. Mol. Sci. 2018, 19, 1798. [CrossRef] [PubMed]
53. Zhang, Y.; Huang, G.; Shornick, L.P.; Roswit, W.T.; Shipley, J.M.; Brody, S.L.; Holtzman, M.J. A transgenic
FOXJ1-Cre system for gene inactivation in ciliated epithelial cells. Am. J. Respir. Cell Mol. Biol. 2007, 36,
515–519. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
